Delivery of oligonucleotides with lipid nanoparticles.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Advanced Drug Delivery Reviews

• Publication date

  2015-06-29

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.addr.2015.02.007PMID 25733311PMCID PMC4539950
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates

  2014cited by this paper
• Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide

  2014cited by this paper
• The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice.

  2014cited by this paper
• Anti-miR-197 inhibits migration in HCC cells by targeting KAI 1/CD82.

  2014cited by this paper
• Overcoming nonviral gene delivery barriers: perspective and future.

  2013cited by this paper
• Silencing of miR-21 by locked nucleic acid-lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death.

  2013cited by this paper
• Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics.

  2013cited by this paper
• Effect of unsaturated alkyl chains on transfection activity of poly(amidoamine) dendron-bearing lipids.

  2012cited by this paper
• Doxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES).

  2012cited by this paper
• The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases

  2012cited by this paper
• A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo.

  2012cited by this paper
• Microfluidic technologies for accelerating the clinical translation of nanoparticles.

  2012cited by this paper
• Anti‐miR‐155 oligonucleotide enhances chemosensitivity of U251 cell to taxol by inducing apoptosis

  2012cited by this paper
• Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**

  2012cited by this paper
• Nucleic-acid based gene therapeutics: delivery challenges and modular design of nonviral gene carriers and expression cassettes to overcome intracellular barriers for sustained targeted expression

  2012cited by this paper
• Packaging signals in the 5'-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules.

  2011cited by this paper
• Ionization behavior of amino lipids for siRNA delivery: determination of ionization constants, SAR, and the impact of lipid pKa on cationic lipid-biomembrane interactions.

  2011cited by this paper
• Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity.

  2011cited by this paper
• Microfluidic assembly of lipid-based oligonucleotide nanoparticles.

  2011cited by this paper
• A covalently stabilized lipid-polycation-DNA (sLPD) vector for antisense oligonucleotide delivery.

  2011cited by this paper
• Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery.

  2011cited by this paper
• Rational design of cationic lipids for siRNA delivery

  2010cited by this paper
• Lipid-like materials for low-dose, in vivo gene silencing

  2010cited by this paper
• Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms.

  2010cited by this paper
• Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.

  2010cited by this paper
• Oligonucleotides derived from the packaging signal at the 5′ end of the viral PB2 segment specifically inhibit influenza virus in vitro

  2009cited by this paper
• Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting.

  2009cited by this paper
• [Inhibition of hepatitis B virus (HBV) replication using antisense LNA targeting to both S and C genes in HBV].

  2009cited by this paper
• Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.

  2009cited by this paper
• Development of lipidoid-siRNA formulations for systemic delivery to the liver.

  2009cited by this paper
• Efficient telomerase inhibition in human non-small cell lung cancer cells by liposomal delivery of 2'-O-methyl-RNA.

  2009cited by this paper
• Novel cationic liposome formulation for the delivery of an oligonucleotide decoy to NF-kappaB into activated macrophages.

  2008cited by this paper
• Analysis of the intracellular barriers encountered by nonviral gene carriers in a model of spatially controlled delivery to neurons

  2008cited by this paper
• Progress in developing cationic vectors for non-viral systemic gene therapy against cancer.

  2008cited by this paper
• A combinatorial library of lipid-like materials for delivery of RNAi therapeutics

  2008influential reference
• Lipid-based Nanoparticles for Nucleic Acid Delivery

  2007cited by this paper
• Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses.

  2007cited by this paper
• Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles.

  2007cited by this paper
• RNAi-mediated gene silencing in non-human primates

  2006cited by this paper
• Methods for the preparation of protein-oligonucleotide-lipid constructs.

  2006cited by this paper
• Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.

  2006cited by this paper
• Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo

  2006cited by this paper
• Protection of oligonucleotides against nucleases by pegylated and non-pegylated liposomes as studied by fluorescence correlation spectroscopy.

  2005cited by this paper
• Cationic lipid-protamine-DNA (LPD) complexes for delivery of antisense c-myc oligonucleotides.

  2005cited by this paper
• CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques

  2004cited by this paper
• Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.

  2004cited by this paper
• CpG‐ODN‐stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen‐specific antitumour immunity in a HPV 16 E7‐associated animal tumour model

  2004cited by this paper
• Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides

  2004cited by this paper
• RNA modulation, repair and remodeling by splice switching oligonucleotides.

  2004cited by this paper
• Nanostructure of cationic lipid-oligonucleotide complexes.

  2004cited by this paper
• Inhibition of papilloma progression by antisense oligonucleotides targeted to HPV11 E6/E7 RNA

  2004cited by this paper
• Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes.

  2004cited by this paper
• Modulation of alternative splicing by antisense oligonucleotides.

  2003cited by this paper
• Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.

  2003cited by this paper
• A Protective Role of Locally Administered Immunostimulatory CpG Oligodeoxynucleotide in a Mouse Model of Genital Herpes Infection

  2003cited by this paper
• Immunoprotective Activity and Safety of a RespiratorySyncytial Virus Vaccine: Mucosal Delivery of Fusion Glycoprotein with aCpG OligodeoxynucleotideAdjuvant

  2003cited by this paper
• Barriers to nonviral gene delivery.

  2003cited by this paper
• On the Mechanism of Cationic Amphiphile-mediated Transfection. To Fuse or not to Fuse: Is that the Question?

  2002cited by this paper
• Complex Roles of CpG in Liposomal Delivery of DNA and Oligonucleotides

  2002cited by this paper
• Lipoplex-mediated Transfection of Mammalian Cells Occurs through the Cholesterol-dependent Clathrin-mediated Pathway of Endocytosis*

  2002cited by this paper
• Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome.

  2002cited by this paper
• Lipid-mediated delivery of oligonucleotide to pulmonary endothelium.

  2002cited by this paper
• Cellular Response to an Antisense-mediated Shift of Bcl-x Pre-mRNA Splicing and Antineoplastic Agents*

  2002cited by this paper
• Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors.

  2002cited by this paper
• Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles.

  2002cited by this paper
• HPV E6 antisense induces apoptosis in CaSki cells via suppression of E6 splicing

  2002cited by this paper
• Combinatorial Synthesis of New Cationic Lipids and High‐Throughput Screening of Their Transfection Properties

  2002cited by this paper
• Nonviral Vectors in the New Millennium: Delivery Barriers in Gene Transfer

  2001cited by this paper
• Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures.

  2001influential reference
• Oligonucleotide lipoplexes: the influence of oligonucleotide composition on complexation.

  2001cited by this paper
• Lipid-based formulations of antisense oligonucleotides for systemic delivery applications.

  2000cited by this paper
• A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability.

  2000cited by this paper
• A Toll-like receptor recognizes bacterial DNA

  2000cited by this paper
• Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects.

  2000cited by this paper
• Antisense Oligonucleotides in Cancer

  2000cited by this paper
• Intravenous Administration of Stabilized Antisense Lipid Particles (SALP) Leads to Activation and Expansion of Liver Natural Killer Cells

  2000cited by this paper
• Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects.

  2000cited by this paper
• Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse.

  2000cited by this paper
• Aerosolized Syk Antisense Suppresses Syk Expression, Mediator Release from Macrophages, and Pulmonary Inflammation1

  2000cited by this paper
• Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2.

  1999cited by this paper
• Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria.

  1999cited by this paper
• Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes.

  1998cited by this paper
• A comparison of in vivo gene delivery methods for antisense therapy in ligament healing

  1998cited by this paper
• Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

  1998cited by this paper
• Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation.

  1998cited by this paper
• Biodistribution, stability, and antiviral efficacy of liposome‐entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection

  1998cited by this paper
• Inhibition of influenza virus replication by phosphorothioate and liposomally endocapsulated oligonucleotides.

  1998cited by this paper
• Liposomal delivery of a 30-mer antisense oligodeoxynucleotide to inhibit proopiomelanocortin expression.

  1998cited by this paper
• An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery.

  1998cited by this paper
• Optimization of lipid-mediated ribozyme delivery to cells in culture.

  1997cited by this paper
• Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer

  1997cited by this paper
• Structure of DNA-Cationic Liposome Complexes: DNA Intercalation in Multilamellar Membranes in Distinct Interhelical Packing Regimes

  1997cited by this paper
• [Antisense nucleic acid therapy of influenza virus].

  1997cited by this paper
• Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.

  1997cited by this paper
• Intracellular Distribution and Mechanism of Delivery of Oligonucleotides Mediated by Cationic Lipids

  1996cited by this paper
• Potentiation of cationic liposome-mediated gene delivery by polycations.

  1996cited by this paper
• Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes.

  1996cited by this paper
• Mechanism of oligonucleotide release from cationic liposomes.

  1996cited by this paper
• Complexes between cationic liposomes and DNA visualized by cryo-TEM.

  1995cited by this paper
• Antisense phosphorothioates as antivirals against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

  1995cited by this paper

• Study of the interaction between graphene oxide and cholesterol using different artificial membrane models.

  2026cites this paper
• Bioconjugates for improved delivery of oligonucleotide therapeutics to the central nervous system.

  2026cites this paper
• Recent advances in the nanoparticle-based targeted cancer treatment: A review

  2026cites this paper
• Liposome-engineered therapeutics: A promising frontier in ovarian cancer treatment.

  2025cites this paper
• Stimuli-Responsive Nanomaterials for the Precision Delivery of mRNA Cancer Vaccines

  2025cites this paper
• Microfluidic Platforms for Ex Vivo and In Vivo Gene Therapy

  2025cites this paper
• Reducing Complexity in Lipid Nanoparticles: Three-Component Zwitterionic Amino Lipids for Targeted Extrahepatic mRNA Delivery.

  2025cites this paper
• Delivery strategies for RNA-targeting therapeutic nucleic acids and RNA-based vaccines against respiratory RNA viruses: IAV, SARS-CoV-2, RSV

  2025cites this paper
• High-density lipoprotein-like nanoparticles with cationic cholesterol derivatives for siRNA delivery.

  2025cites this paper
• The Plethora of RNA–Protein Interactions Model a Basis for RNA Therapies

  2025cites this paper
• Multi‐Step Assembly of an RNA‐Liposome Nanoparticle Formulation Revealed by Real‐Time, Single‐Particle Quantitative Imaging

  2025cites this paper
• Targeting VSMCs to suppress macrophage-like phenotype switching that restrains atherogenesis by immunosuppressive oligodeoxynucleotide (A151) functionalized selenium nanoparticles

  2025cites this paper
• Liposome-mediated gene delivery: A comprehensive review of biophysical parameters, lipid composition and targeting strategies

  2025cites this paper
• Tracking the Endosomal Escape of Nanoparticles in Live Cells Using a Triplex‐Forming Oligonucleotide

  2024cites this paper
• Antisense oligonucleotides-based approaches for the treatment of multiple myeloma.

  2024cites this paper
• Antigen-specific T cell immunotherapy by in vivo mRNA delivery

  2024cites this paper
• Nanoparticles for Cancer Gene Therapy and Imaging

  2024cites this paper
• Oral Microto-Nano Genome-Editing System Enabling Targeted Delivery and Conditional Activation of CRISPR-Cas9 for Gene Therapy of Inflammatory Bowel Disease.

  2024cites this paper
• Nanocarriers: Exploring the Potential of Oligonucleotide Delivery.

  2024cites this paper
• Fine-tuning of membrane permeability by reversible photoisomerization of aryl-azo derivatives of thymol embedded in lipid nanoparticles.

  2024cites this paper
• Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress

  2024cites this paper
• Non‐coding RNAs to treat vascular smooth muscle cell dysfunction

  2024cites this paper
• Breaking the barriers in management of Alzheimer's disease through cationic nanoformulation: A review

  2024cites this paper
• Bi-specific nanoparticle-based engager capable of in situ activation of anti-tumor immune responses for postoperative cancer immunotherapy

  2024cites this paper
• Delivery of nucleic acid drugs for tumor therapy: Opportunities and challenges

  2024cites this paper
• NIR light-controlled DNA nanodevice for amplified mRNA imaging and precise gene therapy

  2024cites this paper
• Microfluidic devices for the detection of disease-specific proteins and other macromolecules, disease modelling and drug development: A review.

  2023cites this paper
• Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity

  2023cites this paper
• Cryo-TEM Reveals the Influence of Multivalent Charge and PEGylation on Shape Transitions in Fluid Lipid Assemblies: From Vesicles to Discs, Rods, and Spheres.

  2023cites this paper
• The Influence of Multivalent Charge and PEGylation on Shape Transitions in Fluid Lipid Assemblies: From Vesicles to Discs, Rods, and Spheres

  2023cites this paper
• Versatility of Liposomes for Antisense Oligonucleotide Delivery: A Special Focus on Various Therapeutic Areas

  2023cites this paper
• Next-generation poly-L-histidine formulations for miRNA mimic delivery

  2023cites this paper
• Carbon Dots with Guanidinium and Amino Acid Functional Groups for Targeted Small Interfering RNA Delivery toward Tumor Gene Therapy.

  2023cites this paper
• Nanomedicine based strategies for oligonucleotide traversion across the blood-brain barrier.

  2023cites this paper
• Effect of drug-to-lipid ratio on nanodisc-based tenofovir drug delivery to the brain for HIV-1 infection

  2022cites this paper
• Promises of Molecular Pharmaceutics in the Development of Novel Drug Delivery Formulations.

  2022cites this paper
• Emerging pyroptosis-engineered nanobiotechnologies regulate cancers and inflammatory diseases: A double-edged sword

  2022cites this paper
• A perspective on oligonucleotide therapy: Approaches to patient customization

  2022cites this paper
• TLR3 agonist nanoscale coordination polymer synergizes with immune checkpoint blockade for immunotherapy of cancer.

  2022cites this paper
• New concepts in wound targeting through liposome-based nanocarriers (LBNs)

  2022cites this paper
• Lipid-based nucleic acid therapeutics with in vivo efficacy.

  2022cites this paper
• Extracellular vesicle expansion of PMIS‐miR‐210 expression inhibits colorectal tumour growth via apoptosis and an XIST/NME1 regulatory mechanism

  2022cites this paper
• Nanomaterial-Based Drug Delivery System Targeting Lymph Nodes

  2022influential citation
• Multi-step screening of DNA/lipid nanoparticles and co-delivery with siRNA to enhance and prolong gene expression

  2022cites this paper
• RNA-based therapeutics: an overview and prospectus

  2022cites this paper
• The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases

  2022cites this paper
• Size-tunable PEG-grafted copolymers as a polymeric nanoruler for passive targeting muscle tissues.

  2022cites this paper
• In Vitro CRISPR/Cas9 Transfection and Gene-Editing Mediated by Multivalent Cationic Liposome–DNA Complexes

  2022cites this paper
• Delivery and Controllable Release of Anti-Sense DNA Based on Frame-Guided Assembly Strategy

  2022cites this paper
• Targeting nucleic acid-based therapeutics to tumors: Challenges and strategies for polyplexes.

  2022cites this paper
• Melatonin Engineered Adipose-Derived Biomimetic Nanovesicles Regulate Mitochondrial Functions and Promote Myocardial Repair in Myocardial Infarction

  2022cites this paper
• Carrier strategies boost the application of CRISPR/Cas system in gene therapy

  2022cites this paper
• Microfluidic Fabrication of Lipid Nanoparticles for the Delivery of Nucleic Acids.

  2022cites this paper
• 2′-O-(N-(Aminoethyl)carbamoyl)methyl Modification Allows for Lower Phosphorothioate Content in Splice-Switching Oligonucleotides with Retained Activity

  2022cites this paper
• Long Noncoding RNAs as Therapeutic Targets.

  2022cites this paper
• Delivery of Oligonucleotide Therapeutics for Macrophage Reprogramming in Inflammatory Diseases

  2022cites this paper
• Next generation self-replicating RNA vectors for vaccines and immunotherapies

  2022cites this paper
• Protective Effect of Edaravone against Cationic Lipid-Mediated Oxidative Stress and Apoptosis.

  2021cites this paper
• Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1

  2021cites this paper
• Transferrin Receptor Targeted Polyplexes Completely Comprised of Sequence-defined Components.

  2021cites this paper
• Cationic lipid-based formulations for encapsulation and delivery of anti-EFG1 2'OMethylRNA oligomer.

  2021cites this paper
• In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles

  2021cites this paper
• A Systematic Approach for Liposome and Lipodisk Preclinical Formulation Development by Microfluidic Technology

  2021cites this paper
• Nanomedicine and gene delivery

  2021cites this paper
• Synthesis and short DNA in situ loading and delivery of 4 nm-aperture flexible organic frameworks

  2021cites this paper
• Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem

  2021cites this paper
• Therapeutic Potential of Nucleic Acids when Combined with Extracellular Vesicles

  2021cites this paper
• The development and improvement of ribonucleic acid therapy strategies

  2021cites this paper
• Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal Model

  2021cites this paper
• Recent trends of NFκB decoy oligodeoxynucleotide-based nanotherapeutics in lung diseases.

  2021cites this paper
• Delivery of therapeutic oligonucleotides in nanoscale

  2021influential citation
• Therapeutic strategies for modulating epigenetic mechanisms in cardiovascular disease

  2021cites this paper
• Paclitaxel loading in cationic liposome vectors is enhanced by replacement of oleoyl with linoleoyl tails with distinct lipid shapes

  2021cites this paper
• Nano-ghosts: Novel biomimetic nano-vesicles for the delivery of antisense oligonucleotides.

  2021cites this paper
• Aerosolizable siRNA-Encapsulated Solid Lipid Nanoparticles Prepared by Thin-film Freeze-Drying for Potential Pulmonary Delivery.

  2021cites this paper
• Recent advancements in liposome technology.

  2020cites this paper
• Oligonucleotide–Polymer Conjugates: From Molecular Basics to Practical Application

  2020cites this paper
• Long Non-coding RNAs Mechanisms of Action in HIV-1 Modulation and the Identification of Novel Therapeutic Targets

  2020cites this paper
• Encapsulation of Apoptotic Proteins in Lipid Nanoparticles to Induce Death of Cancer Cells

  2020cites this paper
• In Vitro Delivery of Cell Impermeable Phallotoxin Using Cationic Liposomes Composed of Lipids Bearing Lysine Headgroup.

  2020cites this paper
• Delivery of nucleic acid therapeutics for cancer immunotherapy

  2020cites this paper
• Immunoactive drug carriers in cancer therapy

  2020cites this paper
• Micelleplexes as nucleic acid delivery systems for cancer-targeted therapies.

  2020cites this paper
• Membrane-core nanoparticles for cancer nanomedicine.

  2020cites this paper
• Computational insights of two‐dimensional infrared spectroscopy under electric fields in phosphorylcholine

  2020cites this paper
• Grafting multi-maleimides on antisense oligonucleotide to enhance its cellular uptake and gene silencing capability.

  2020cites this paper
• Progress in arginine-based gene delivery systems.

  2020cites this paper
• Lipid nanoparticle technology for therapeutic gene regulation in the liver

  2020cites this paper
• DNA Nanotechnology: From Structure to Functionality

  2020cites this paper
• Biomineralized metal–organic framework nanoparticles enable a primer exchange reaction-based DNA machine to work in living cells for imaging and gene therapy

  2020cites this paper
• Assembly of Building Blocks by Double-End-Anchored Polymers in the Dilute Regime Mediated by Hydrophobic Interactions at Controlled Distances.

  2020cites this paper
• Non-Viral Targeted Nucleic Acid Delivery: Apply Sequences for Optimization

  2020cites this paper
• New Nanomaterials and Techniques for Tumor-targeted Systems

  2020cites this paper
• A simple self-adjuvanting biomimetic nanovaccine self-assembled with the conjugate of phospholipids and nucleotides can induce a strong cancer immunotherapeutic effect.

  2020cites this paper
• Analytical characterization of liposomes and other lipid nanoparticles for drug delivery.

  2020cites this paper
• Enhanced Loading of Paclitaxel in Cationic Liposomes by Replacement of Oleoyl with Linoleoyl Lipid Tails with Benefits in Cancer Therapeutics from In Vitro Studies

  2020cites this paper
• A Nanoparticle Platform for Accelerated In Vivo Oral Delivery Screening of Nucleic Acids

  2020cites this paper
• Lipid-Based Tumor-targeted Systems

  2020cites this paper
• Recent Advances in Microfluidics for the Preparation of Drug and Gene Delivery Systems.

  2020cites this paper
• Nanodelivery of immunogenic cell death-inducers for cancer immunotherapy.

  2020cites this paper